Back

Efficacy and safety of alirocumab 300mg in real-world clinical practice: preliminary data from the ALINET Registry

29 August 2025 (10:00 - 10:45)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (1) - Dyslipidaemias: current strategies and innovations Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Ciro Cotticelli

University of Naples Federico II, Naples (Italy)

9 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Doctor Z. Zhang (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Doctor E. Bolsteina (Riga, LV)
Abstract Slides
Presentation thumbnail
Ms H. Shen (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Professor S. Hong (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (1) - Dyslipidaemias: current strategies and innovations

The Event

Event poster

ESC Congress 2025

29 August 2025 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of Alirocumab once-monthly dosing in patients with atherosclerotic cardiovascular disease and without acute coronary syndrome or stroke; an ODYSSEY CHOICE I analysis
thumbnail
Congress Presentation
Real-world evidence or real-world reality - Is Real world evidence a mirror or magnifier of RCTs?
thumbnail
Congress Presentation
Beyond LDL-cholesterol: effects of alirocumab on the human apolipoproteome

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources